Holen Sie sich die Stockscreener-App
67.32
1.99%
-1.49
Schlusskurs vom Vortag:
$68.81
Offen:
$68.86
24-Stunden-Volumen:
338.76K
Relative Volume:
0.28
Marktkapitalisierung:
$5.58B
Einnahmen:
$1.73B
Nettoeinkommen (Verlust:
$682.64M
KGV:
8.7017
EPS:
7.7364
Netto-Cashflow:
$411.18M
1W Leistung:
-4.08%
1M Leistung:
-1.16%
6M Leistung:
-21.81%
1J Leistung:
+46.83%
1-Tages-Spanne:
$67.17
$69.23
1-Wochen-Bereich:
$67.17
$72.00
52-Wochen-Spanne:
$43.17
$87.50
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Firmenname
Ptc Therapeutics Inc
Sektor
Branche
Telefon
(908) 222-7000
Adresse
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
67.32 | 5.71B | 1.73B | 682.64M | 411.18M | 7.7364 |
VRTX
Vertex Pharmaceuticals Inc
|
436.96 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
637.05 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.41 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.00 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.91 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Eingeleitet | Raymond James | Outperform |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2025-12-01 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-17 | Eingeleitet | Truist | Buy |
| 2025-05-09 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-05-07 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-03-11 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-12-13 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-09-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-08-26 | Fortgesetzt | UBS | Buy |
| 2024-05-20 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-30 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Herabstufung | Citigroup | Neutral → Sell |
| 2023-10-06 | Herabstufung | Truist | Buy → Hold |
| 2023-09-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-09-15 | Herabstufung | Raymond James | Outperform → Underperform |
| 2023-03-17 | Eingeleitet | SVB Securities | Market Perform |
| 2022-12-14 | Eingeleitet | Goldman | Sell |
| 2022-09-12 | Eingeleitet | Jefferies | Buy |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-29 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-11-30 | Herabstufung | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-10-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-04-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-02-20 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-05-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Eingeleitet | Bernstein | Outperform |
| 2018-10-03 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-06-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Ptc Therapeutics Inc Aktie (PTCT) Neueste Nachrichten
PTC Therapeutics, Inc. $PTCT Position Raised by Jefferies Financial Group Inc. - MarketBeat
Thrivent Financial for Lutherans Makes New $4.19 Million Investment in PTC Therapeutics, Inc. $PTCT - MarketBeat
United States Duchenne Muscular Dystrophy Therapeutics Market - openPR.com
BofA reiterates Buy on PTC Therapeutics stock citing Sephience launch momentum - Investing.com
PTC Therapeutics’ SWOT analysis: stock gains on rare disease drug launch - Investing.com India
PTC Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Q3 2025 PTC Therapeutics Inc Earnings Call Transcript - GuruFocus
PTC Therapeutics Q1 earnings call highlights - MSN
PTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 2,812 Shares - MarketBeat
PTC Therapeutics (PTCT) CLO exercises options and sells 2,812 shares under 10b5-1 plan - Stock Titan
Oregon Public Employees Retirement Fund Invests $1.39 Million in PTC Therapeutics, Inc. $PTCT - MarketBeat
Analyst Forecasts For PTC Therapeutics, Inc. (NASDAQ:PTCT) Are Surging Higher - Sahm
Party Time: Brokers Just Made Major Increases To Their PTC Therapeutics, Inc. (NASDAQ:PTCT) Earnings Forecasts - 富途牛牛
PTC Therapeutics CEO Matthew B. Klein sells $917,153 in stock By Investing.com - Investing.com South Africa
PTC Therapeutics CEO Matthew B. Klein sells $917,153 in stock - Investing.com
PTC Therapeutics (PTCT) CEO earns 12,500 RSUs, sells 12,572 shares for tax withholding - Stock Titan
TD Bank holds 3,025,945 PTC Therapeutics shares (NASDAQ: PTCT) — 3.7% - Stock Titan
Janus Henderson Group (NASDAQ: PTCT) holds 8.7% of PTC Therapeutics (7.19M shares) - Stock Titan
Form 144 notice — PTCT reports 2,812-share resale (PTCT) - Stock Titan
Matthew Klein sells PTCT shares; restricted stock vests (PTCT) - Stock Titan
PTCT (NASDAQ: PTCT) director sells shares; restricted stock vests - Stock Titan
PTC Therapeutics stock (US69366J2006): Rare disease focus amid biotech sector momentum - AD HOC NEWS
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Mark Elliott Boulding Sells 3,540 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
[Form 4] PTC THERAPEUTICS, INC. Insider Trading Activity - Stock Titan
Barclays Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $120 - Moomoo
Why PTC Therapeutics (PTCT) Is Up 12.5% After Beating Q1 Estimates And Lifting 2026 Guidance - Sahm
New Forecasts: Here's What Analysts Think The Future Holds For PTC Therapeutics, Inc. (NASDAQ:PTCT) - Yahoo Finance Australia
J.P. Morgan Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $89 - Moomoo
State of New Jersey Common Pension Fund D Sells 19,078 Shares of PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics : Corporate Presentation – May 2026 - marketscreener.com
PTCT Soars As PTC Therapeutics Lifts 2026 Guidance And Beats Earnings - timothysykes.com
PTC Therapeutics stock sinks as pivotal data fails to calm sellers - MSN
PTC Therapeutics: Sephience Turns The Story From Regulatory Repair To Operating Leverage - Seeking Alpha
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q1 2026 Earnings Call Transcript - Insider Monkey
PTC Therapeutics (PTCT) Gets a Buy from Raymond James - The Globe and Mail
PTC Therapeutics, Inc. $PTCT Shares Purchased by Comerica Bank - MarketBeat
PTC Therapeutics Raised to Buy From Hold by TD Cowen - Moomoo
PTCT Upgraded by TD Cowen -- Price Target Raised to $90 - GuruFocus
PTC Therapeutics (NASDAQ:PTCT) Releases Quarterly Earnings Results, Beats Estimates By $0.42 EPS - MarketBeat
PTC Therapeutics Lifts 2026 Outlook on Sephience Momentum - The Globe and Mail
PTC Therapeutics Q1 Earnings Call Highlights - MarketBeat
PTCT Maintains by RBC Capital -- Price Target Raised to $82.00 - GuruFocus
PTCT (NASDAQ: PTCT) affiliate plans to sell 3,540 shares; prior insider sales listed - Stock Titan
PTC Therapeutics Gains Fresh Nasdaq Today Attention - Kalkine Media
PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $82.00 at Royal Bank Of Canada - MarketBeat
Update: PTC Therapeutics Shares Rise After Q1 Results Beat Consensus - Moomoo
RBC Capital Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Raises Target Price to $82 - Moomoo
PTCT Stock Jumps As Earnings Beat And Drug Data Fuel Bullish Momentum - StocksToTrade
PTCT Maintains Overweight Rating -- Price Target Raised to $95.0 - GuruFocus
PTC Therapeutics climbs after guidance hike (PTCT:NASDAQ) - Seeking Alpha
Finanzdaten der Ptc Therapeutics Inc-Aktie (PTCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ptc Therapeutics Inc-Aktie (PTCT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Boulding Mark Elliott | EXEC. VP AND CLO |
May 15 '26 |
Sale |
72.18 |
2,812 |
202,958 |
105,212 |
| Klein Matthew B. | CHIEF EXECUTIVE OFFICER |
May 14 '26 |
Sale |
72.95 |
12,572 |
917,154 |
393,998 |
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):